WS
IMMU

Wedbush Securities’s Immunomedics Inc IMMU Stock Holding History

Wedbush Securities’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-14,500
Closed -$34K – 877
2016
Q2 		$34K Buy
+14,500
New +$48.5K 0.01% 751

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wedbush Securities's IMMU Position: Q3 2016 in Review

Wedbush Securities sold out of Immunomedics Inc (IMMU) in Q3 2016, closing a stake of 14,500 shares — an estimated $34K sold.

Wedbush Securities first reported a position in IMMU in Q2 2016 and held it in 1 quarter. The position peaked at $34K in Q2 2016. 101 funds tracked by Wall St. Rank hold IMMU as of Q3 2016.

  • Wedbush Securities reported no remaining Immunomedics Inc position as of Q3 2016 after selling out during the quarter.
  • Wedbush Securities sold 14,500 Immunomedics Inc shares in Q3 2016, an estimated $34K.
  • Wedbush Securities first reported a position in Immunomedics Inc in Q2 2016 and held it in 1 quarter.
  • Wedbush Securities's Immunomedics Inc position peaked at $34K in Q2 2016.
  • 101 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2016.

Based on Wedbush Securities's 13F filing for Q3 2016, filed 4 Nov 2016.